English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/138212
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Antivascular and antitumor properties of the tubulin-binding chalcone TUB091

AuthorsCanela, María-Dolores ; Noppen, Sam; Bueno, Oskía; Prota, Andrea E.; Bargsten, Katja; Sáez-Calvo, Gonzalo; Jimeno, M. Luisa ; Benkhei, Mohammed; Ribatti, Domenico; Velázquez, Sonsoles ; Camarasa Rius, María José ; Díaz, José Fernando ; Steinmetz, Michel O.; Priego, Eva María ; Peréz-Pérez, María-Jesús ; Liekens, Sandra
Drug research
Issue Date20-May-2016
PublisherImpact Journals
CitationOncotarget, Advance Publication (2016)
AbstractWe investigated the microtubule-destabilizing, vascular-targeting, anti-tumor and anti-metastatic activities of a new series of chalcones, whose prototype compound is (E)-3-(3’’-amino-4’’-methoxyphenyl)-1-(5’-methoxy-3’,4’-methylendioxyphenyl)- 2-methylprop-2-en-1-one (TUB091). X-ray crystallography showed that these chalcones bind to the colchicine site of tubulin and therefore prevent the curved-tostraight structural transition of tubulin, which is required for microtubule formation. Accordingly, TUB091 inhibited cancer and endothelial cell growth, induced G2/M phase arrest and apoptosis at 1-10 nM. In addition, TUB091 displayed vascular disrupting effects in vitro and in the chicken chorioallantoic membrane (CAM) assay at low nanomolar concentrations. A water-soluble L-Lys-L-Pro derivative of TUB091 (i.e. TUB099) showed potent antitumor activity in melanoma and breast cancer xenograft models by causing rapid intratumoral vascular shutdown and massive tumor necrosis. TUB099 also displayed anti-metastatic activity similar to that of combretastatin A4-phosphate. Our data indicate that this novel class of chalcones represents interesting lead molecules for the design of vascular disrupting agents (VDAs). Moreover, we provide evidence that our prodrug approach may be valuable for the development of anti-cancer drugs.
Publisher version (URL)http://dx.doi.org/10.18632/oncotarget.9527
Appears in Collections:(CENQUIOR) Artículos
(IQM) Artículos
(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Oncotarget.pdf18,37 MBAdobe PDFThumbnail
Show full item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.